EST Olema Oncology (OLMA) files $200M mixed securities shelfDon't Miss Our New Year's Offers:Discover the latest stocks recommended by ...

Olema Pharmaceuticals, Inc. (“Olema” or “”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast ...

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies ...

Geode Capital Management LLC reduced its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Free Report) by 11.8% ...

SAN FRANCISCO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical ...

Nearly a year after Marin County supervisors approved new regulations for short-term rentals, the planning staff is moving to implement them. Under the new regulations, anyone who has a business ...

Olema Pharmaceuticals will present at the J.P. Morgan Healthcare Conference on January 14, 2025, discussing its breast cancer therapies. Olema Pharmaceuticals, Inc., a clinical-stage ...

Olema Pharmaceuticals Inc (OLMA) stock saw a modest uptick, ending the day at $5.83 which represents a slight increase of $0.22 or 3.92% from the prior close of $5.61. The stock opened at $5.61 and ...

SAN FRANCISCO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical ...

SAN FRANCISCO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical ...

The company is not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale by the selling stockholders of the shares offered by this prospectus.